Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)

Inclusion Criteria:

• Willingness to sign an informed consent

• Age:14~60 years, regardless of gender

• Clinical evaluation and renal biopsy diagnostic for IgAN, excluded secondary IgAN.Renal histological criteria should be defined by Lee's glomerular grading system.

• 1 g/day <= proteinuria < 3.5 g/day, or UPr/Cr ratio ≥ 0.6 (male) or ≥ 0.8 (female)when taking ARB

• eGFR ≥ 40 mL/min/1.73 m2

Exclusion Criteria:

• Inability or unwillingness to sign the informed consent

• Inability or unwillingness to meet the scheme demands raised by the investigators

• Rapidly progressive nephritic syndrome and acute renal failure, including rapidlyprogressive IgAN ( IgAN with rapid decline in renal function characterizedhistologically by necrotizing vasculitis and crescent formation≥30%) necessitating theuse of other immunosuppressive agents.

• Secondary IgAN such as systemic lupus erythematosus, Henoch-Schonlein purpuricnephritis and hepatitis B -associated nephritis

• est GFR < 40 mL/min/1.73m2

• Malignant hypertension that is difficult to be controlled by oral drugs

• Cirrhosis, chronic active liver disease.

• History of significant gastrointestinal disorders (e.g. severe chronic diarrhea oractive peptic ulcer disease.)

• Any Active systemic infection or history of serious infection within one month ofentry or known infection with HIV, hepatitis B, or hepatitis C.

• Other major organ system disease (e.g. serious cardiovascular diseases includingcongestive heart failure , chronic obstructive pulmonary disease, asthma requiringoral steroid treatment or central nervous system diseases)

• Malignant tumors (except fully cured basal cell carcinoma)

• Absolute neutrophil count ＜ 1500／mm3, absolute platelet count ＜75000／mm3 or hematocrit (Hct) <28% (anemic subjects may be reevaluated after the anemia has been treated.)

• Known allergy, contraindication or intolerance to the MMF, corticosteroids orACEI/ARB.

• Pregnancy or breast feeding at the time of entry or unwillingness to comply withmeasures for contraception

• Current exposure to MMF or azathioprine. In case of current treatment with oralsteroid or ACEI/ARB, entry is permitted after corticosteroids or ACEI/ARB are stoppedfor 2 weeks.

• Current or recent (within 30 days) exposure to any other investigational drugs